Morepen lab financial report highlighted, First Half (H1) FY 2019-20 (Standalone) Net Sales Revenue recorded a growth of 24.2 per cent at Rs. 383.30 crore in H1 FY 2019-20 as compared to Rs. 308.56 crore in the corresponding first half of the previous fiscal. EBIDTA was up by 31.8 per cent in H1 FY 2019-20 at Rs. 37.44 crores (Rs. 28.40 crores) and Cash profit during the same period was up by around 32.4 per cent at Rs. 36.63 crores (Rs. 27.67 crores). Net Profit before tax went up by 87.5 per cent in H1 FY 2019-20 at Rs. 18.10 crore (Rs. 9.65 crore). The Net Profit after Tax during the period stood at Rs. 12.95 crore up by 34.1 per cent from Rs. 9.65 crore net profit registered in the corresponding period of FY;2018-19.

API sales were up by 37 percent at Rs. 228.79 crores in H1 FY 2019-20 constituting 60 per cent of the total turnover. Within the API segment Exports registered an impressive growth of 46 percent at Rs. 172 crore. Export sales in H1; FY 2019-20 for Montelukast Sodium rose by 156 per cent and that of Atorvastatin Calcium by 43 percent vis-a-vis the corresponding first half of the previous fiscal. In domestic market Atorvastatin registered growth of about 172 per cent during the same period. Blood Glucose Monitors and Nebulisers half-yearly sales grew by 33 percent and 60 percent respectively